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RESUMO
O objeti vo do presente trabalho é classifi -
car o grau de mucosite oral de acordo com 
os parâmetros internacionais do Common 
Toxicity Criterion (CTC) em pacientes por-
tadores de tumor de cabeça e pescoço 
submeti dos à radioterapia e quimioterapia 
concomitantes, e caracterizar um perfi l dos 
pacientes em nosso meio, verifi cando os 
hábitos dos indivíduos, as característi cas 
do tumor, o protocolo de tratamento e a 
intensidade desta reação aguda. Neste 
estudo foram avaliados 50 pacientes, sub-
meti dos à radioterapia em megavoltagem 
com doses entre 66 a 70 Gy e quimiotera-
pia com cisplati na ou carboplati na conco-
mitante. Semanalmente foi avaliado o grau 
de mucosite de acordo com o  CTC, uma 
escala ordinal que apresenta 4 graus. Ob-
servou-se interrupção do tratamento por 
mucosite em 36% do total de pacientes e 
em 100% dos pacientes diabéti cos, o que 
nos permiti u verifi car que esta patologia 
contribui para a gravidade da mucosite
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ABSTRACT
The objecti ve of present study was to clas-
sify oral mucositi s according to the Com-
mon Toxicity Criterion (CTC) internati onal 
parameters in head and neck tumor pa-
ti ents simultaneously treated with radio and 
chemotherapy, and characterize a pati ent 
profi le in our area, observing the individu-
als’ habits, tumor characteristi cs, treatment 
protocol and acute reacti on intensity. Fift y 
pati ents undergoing simultaneous 66 to 70 
Gy megavoltage radiotherapy and cisplati n/
carboplati n chemotherapy were evaluated 
in this study. Weekly evaluati ons of the de-
gree of mucositi s were perfoemed accord-
ing to CTC, a four-degree ordinal scale; 36% 
of all pati ents and 100% of those with diabe-
tes disconti nued treatment due to mucosi-
ti s, showing that this pathology contributes 
to the severity of mucositi s.
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RESUMEN 
El trabajo objeti vó clasifi car el grado de 
Mucositi s ora de acuerdo a parámetros 
internacionales del CTC en pacientes por-
tadores de tumores de cabeza y cuello 
someti dos a radioterapia y quimioterapia 
concomitantes, y caracterizar un perfi l de 
pacientes en nuestro medio, verifi cando 
hábitos de los individuos, característi cas 
del tumor, protocolo de tratamiento e in-
tensidad de esta reacción aguda. Fueron 
evaluados 50 pacientes someti dos a ra-
dioterapia en megavoltaje con dosis entre 
66 y 70 G y quimioterapia con cisplati no o 
carboplati no concomitante. Se evaluó se-
manalmente el grado de Mucositi s según 
el Common Toxicity Criterio – CTC, una es-
cala ordinal que presenta cuatro grados. Se 
observó interrupción del tratamiento por 
Mucositi s en 36% del total de pacientes y 
en 100% de los pacientes diabéti cos, lo que 
nos permite verifi car que dicha patología 
potencia la gravedad de la mucositi s.
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Mucositis causes 
signifi cant pain, 
chewing and 
swallowing diffi culties 
and is considered the 
most debilitating acute 
reaction during head 
and neck 
cancer treatment.
INTRODUCTION
Head and neck cancer comprises all carcinomas origi-
nati ng in the muco-squamous epithelium, ranging from 
the lips, oral and nasal caviti es, pharynx to the larynx and 
middle ear. It is the third most prevalent tumor around the 
world and represents 7% of the 22.4 million people diag-
noses with cancer, excluding non-melanoma skin cancer(1).
With regard to Brazil, in 2010, about 14,120 new cases 
of mouth cancer occurred. This fi gure corresponds to the 
fi ft h most incident cancer among men and the seventh 
among women(2). 
The treatments used for this disease involve three mo-
daliti es: surgery, radiotherapy and chemotherapy, which 
can be administered exclusively or concomitantly(3).
Head and neck cancer pati ents who receive radio-
therapy can develop reacti on of diﬀ erent intensiti es in 
the mucosa. The associati on between radio and chemo-
therapy increases the incidence, severity and durati on of 
oral mucositi s, especially when combinati ons of diﬀ erent 
drugs and hyperfracti onati on schedules are 
used(4). 
Mucositi s causes signifi cant pain, chew-
ing and swallowing diﬃ  culti es and is con-
sidered the most debilitati ng acute reacti on 
during head and neck cancer treatment(3).
The mechanism through which muco-
siti s occurs is based on the fact that oral 
mucositi s presents high levels of mitoti c 
acti vity and high cell turnover. Due to the 
high degree of cell desquamati on, there is 
a conti nuous need for cell multi plicati on to 
recover the oral mucosa. Tissues with high 
levels of mitoti c acti vity respond rapidly to the radiati on, 
as the most sensiti ve phases of the cell cycle are G2 and 
mitosis. Thus, the mucosa is rapidly aﬀ ected(5). The same 
is true for chemotherapeuti c drugs. These interfere in the 
cell proliferati on and division process. The fact that the 
mucous membranes are constantly renewed makes them 
extremely sensiti ve to the acti on of these drugs(5-6). 
Among the methods used to assess the mucositi s de-
gree in clinical practi ce, it is important to highlight that 
adequate mucosa assessment is needed before starti ng 
head and neck radiotherapy and chemotherapy, as well 
as during treatment. A good assessment method needs 
to consider the pati ent’s report, physical and nutriti onal 
status and a detailed oral cavity inspecti on(5,7). 
Among the diﬀ erent mucositi s classifi cati on scales, an 
analysis of 400 studies show that 43% use the scale of the 
Nati onal Cancer Common Toxicity Criteria (NCI-CTC), 38% 
use the World Health Organizati on (WHO) scale, 10% use 
specifi c scales and 5% use scales by collaborati ng groups, 
such as the scale the Radiati on Therapy Oncology Group 
(RTOG) and the Eastern Cooperati ve Oncology Group 
(ECOG)(5) use. 
In this study, we use the scale of the Nati onal Cancer 
Common Toxicity Criteria (NCI-CTC), as a Portuguese ver-
sion is available which was authorized by the Cancer Ther-
apy Evaluati on Program (CTEP), an NCI organ responsible 
for publishing the table(8). 
In view of the importance of mucositi s during radio-
therapy and chemotherapy for head and neck tumor, this 
study aims to classify the degree of mucositi s according to 
internati onal CTC 2.0 parameters in pati ents submitt ed to 
concomitant radiotherapy and chemotherapy and to ver-
ify whether the individual characteristi cs of pati ents, the 
disease and treatment infl uence the incidence and sever-
ity of the mucositi s. 
LITERATURE REVIEW 
In clinical terms, the installati on of mucositi s is ob-
served two weeks aft er the start of radiotherapy. It starts 
as an infl ammatory process of the mucosa, 
predispositi on to opportunisti c infecti on 
and, depending on its intensity, can evolve 
to ulcerati on. Symptoms are pain and diﬃ  -
culti es to eat, drink and talk. Consequences 
include weight loss and worsening of the pa-
ti ent’s general conditi on(9).
Initi ally, mucositi s is characterized by ep-
ithelial cell deaths and absence of substi tu-
ti on by new cells. Capillary blood vessels be-
come hyperpermeable, leading to mucosal 
edema and decreased blood supply. These 
events determine the appearance of an evo-
luti onary clinical situati on with four phases: 
whitening of the mucosa, erythema, pseudomembrane 
and ulcerati on(7). 
The most important risk factors determining greater 
mucosal cell suscepti bility to radiotherapy and chemo-
therapy are: smoking, treatment type, age, chronic illness-
es like diabetes(9). 
A research accomplished in 1990(10) which involved 41 
smokers who received hyperfracti onated radiotherapy for 
head and neck tumor treatment, showed that pati ents 
who stopped smoking before the start of treatment pre-
sented blander reacti ons. Pati ents were divided in four 
groups: the fi rst included pati ents who had never smoked, 
the second pati ents who had quit smoking before the 
start of treatment, the third those who quit smoking dur-
ing treatment, but soon aft er restarted, and the fourth 
group with pati ents who had not quit smoking at any ti me 
during treatment. It was observed that the durati on of 
mucositi s for pati ents in groups 1 and 2 was 13 weeks, in 
comparison with 21 weeks in groups 3 and 4(10). 
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On the other hand, a research that involved 115 head 
and neck cancer pati ents submitt ed to concomitant radio-
therapy and chemotherapy and aimed to observe the in-
fl uence of cigarett es on tumor response to treatment and 
survival did not demonstrate any diﬀ erence between the 
group of smokers and non-smokers regarding mucositi s 
severity, although pati ents who smoked during treatment 
showed a drop in survival rates(11). 
Specifi cally concerning radiotherapy, some factors can 
infl uence mucositi s severity, including total dose, treated 
volume, fracti oning and treatment ti me(12). One study(13) 
confi rms high incidence levels of mucositi s in  pati ents 
who receive radiotherapy, with 97% for pati ents receiv-
ing radiotherapy in a conventi onal fracti oning schedule, 
100% for pati ents with altered fracti oning (accelerated 
or hyperfracti onated fracti oning) and 89% for pati ents 
receiving conventi onal fracti oning radiotherapy and che-
motherapy at the same ti me. This same study highlights 
that accelerated radiotherapy schedules can infl uence 
mucositi s severity: 53% of pati ents with degree 3 and 4 
mucositi s were submitt ed to radiotherapy with fracti on-
ing alterati ons, in comparison with 34% of pati ents who 
received conventi onal fracti oning and 43 % for pati ents 
treated with conventi onal fracti oning radiotherapy and 
chemotherapy at the same ti me(13). The incidence of de-
gree 3 and 4 mucositi s corresponded to 47% of pati ents 
treated with accelerated or hyperfracti oning. In pati ents 
who received 70Gy with a daily fracti on of 200 cGy for 7 
weeks, the incidence level amounted to 25%(12-13). 
As for age, young pati ents concomitantly submitt ed to 
radiotherapy and chemotherapy are more prone to mu-
cositi s development due to the high mitoti c acti vity of the 
epithelial cells. On the other hand, elderly would be less 
prone to mucositi s due to their low mitoti c acti vity. With 
regard to elderly pati ents submitt ed to chemotherapy, 
however, the physiological decline of the kidney functi on 
can contribute to the development of mucositi s at more 
advanced ages if no dose adjustment is made according 
to the capacity of the pati ent’s kidney functi on. When the 
kidney functi on decreases, excreti on ti me for the drug in-
creases, so that it remains in the body longer and, hence, 
can cause more damage. The relati on between the cell 
replicati on rate and the severity of damage the ionizing 
radiati on causes suggests that, the higher the age, the 
lesser the severity of the reacti ons(14). Another study(15) 
suggested that oral mucosa cell reparati on is impaired 
with aging, contributi ng to the development of more se-
vere mucositi s. 
With regard to diabetes, as this disease entails sys-
temic repercussions, it can infl uence mucositi s severity. 
Research shows that type I and II diabetes pati ents are at 
greater risk of developing gingiviti s and periodontal dis-
ease due to the impaired healing and metalloproteinase 
enzymes’ rapid degradati on of the collagen(16).
METHOD
An observati onal cohort study was developed be-
tween January and December 2006 at a teaching hospital 
in São Paulo City. Approval from the hospital’s Insti tuti on-
al Review Board was obtained under process 0365/05. 
Out of 175 head and neck cancer pati ents forwarded 
to the Radiotherapy Sector, 50 complied with the inclu-
sion criteria. Twenty-one of these were submitt ed to sur-
gery, followed by radiotherapy and adjuvant chemothera-
py, while 29 only received concomitant radiotherapy and 
chemotherapy. 
The inclusion criteria in this study were: Pati ents over 
18 years of age, diagnosed with head and neck cancer 
with histological evidence, in the following primary sites: 
oral cavity, oropharynx, hypopharynx, larynx and maxillary 
sinus, submitt ed to concomitant radiotherapy and chemo-
therapy, who signed the informed consent term.
The following exclusion criteria were adopted: Pa-
ti ents with enhanced trismus, making tge adequate in-
specti on of the oral cavity and oropharynx impossible; 
pati ents submitt ed to another chemotherapy protocol, 
pati ents previously submitt ed to radiotherapy and/or che-
motherapy and pati ents who did not conclude the initi ally 
proposed treatment.
Pati ents were submitt ed to radiotherapy with oppos-
ing parallel cervicofacial fi elds, with the total dose ranging 
between 66 and 70 Gy, in fracti ons of 2gy/day em apa-
relho de megavoltagem. They received chemotherapy 
withReceberam quimioterapia com cisplati na na dose 30 
mg/m2 of cisplati n per week or weekly carboplati n, calcu-
lated according to the plasma concentrati on curve. 
The nurse interviewed the pati ents on the treatment 
planning day. On this occasion, the fi rst mucosa assess-
ment took place, repeated every week during the enti re 
treatment. The radiotherapist assessed the degree of mu-
cositi s, followed by the nurse.
For the interview, a form was prepared with general 
informati on, a history with individual aspects for each pa-
ti ent, disease and treatment characteristi cs. 
The criterion adopted to assess the degree of muco-
siti s was the Common Toxicity Criterion – CTC, which is a 
four-degree ordinal scale: Grade 0-no change; Grade 1-er-
ythema of the mucosa; Grade 2-patchy pseudomembra-
nous reacti on (patches generally = 1.5 cm in diameter and 
non-conti guous); Grade 3-confl uent pseudomembranous 
reacti on (conti guous patches generally > 1.5 in diameter); 
Grade 4-necrosis or deep ulcerati on; may include bleed-
ing not induced by minor trauma or abrasion(8). According 
to the evoluti on of the oral mucositi s during treatment, 
therapeuti c measures were taken, depending on the pre-
sented degree. 
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The parameters for individual clinical characteristi cs of 
the disease, of the mucositi s (global incidence of diﬀ erent 
grades, incidence per anatomic region, grades according 
to weeks of treatment) and main complaints reported by 
the pati ents were submitt ed to descripti ve analysis.
The parameters for the reacti on of the mucosa accord-
ing to individual clinical characteristi cs were submitt ed to 
inferenti al analysis. For the inferenti al analysis, the pa-
ti ents were grouped as follows: pati ents whose treatment 
was not suspended because of the mucositi s (grades 0, 
1 and 2*) and pati ents whose treatment was suspended 
because of the mucositi s (grades 2** and 3). The treat-
ment suspension criterion adopted for grade 2 pati ents 
was reported dysphagia and odynophagia, compromising 
nutriti on and the presence of non-confl uent but patchy 
pseudomembranous reacti on. 
The stati sti cal tests used were: Fisher’s exact test (P) 
and chi-square (x2). 
For all tests, the rejecti on level of the null hypothesis 
was set at 0.05 or 5% (p < 0.05), marking signifi cant rati os 
with an asterisk and non-signifi cant ones with (NS).
RESULTS 
In this study, 45 (90%) pati ents were male and 5 (10%) 
female. The mean age was 58 years, 39 (78%) pati ents 
were white and 11 (22%) black. Fourty (80%) pati ents in-
dicated they had quit smoking before the start of treat-
ment, while 8 (16%) admitt ed they had not quit smoking 
and only 2 (4%) aﬃ  rmed they had never smoked. Only 15 
(30%) pati ents were hypertensive and 3 (6%) diabeti c. 
As for the primary site, 10 pati ents suﬀ ered from oral 
cavity cancer, 32 oropharyngeal, 4 hypopharyngeal, 3 la-
ryngeal and 1 maxillary sinus cancer. 
A predominance of grade 1 and 2 mucositi s was ob-
served (68%) (Picture 1), with higher incidence levels in 
the oropharyngeal region (51%) (Picture 2), between the 
third and sixth week of treatment (Picture 3). 
Of all pati ents, 86% had their treatment interrupted 
at some ti me, in 36% of treatment due to mucositi s. The 
mean interrupti on ti me was 5.9 days. 
The main complaints the pati ents reported aft er the 
start of treatment were loss of taste (41%) and xerostomia 
(29%) (Picture 4). 
Picture 3 – Grade of mucositis according to treatment weeks
Picture 4 – Main patient complaints
Picture 1 – Incidence of different grades of mucositis
Picture 2 – Incidence of mucositis according to topography
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The analysis of pati ents’ individual clinical characteris-
ti cs, disease and treatment characteristi cs showed that di-
abetes signifi cantly increases mucositi s severity (Table 1). 
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DISCUSSION
Mucositi s is quite a common complicati on in head 
and neck cancer pati ents treated with chemotherapy and 
radiotherapy. It is associated with discomfort and intake 
and swallowing diﬃ  culty, and its consequences can range 
from treatment interrupti on to nasogastric probe use and 
hospitalizati on(9).
In this research, the predominance of grade 1 (30%) 
and 2 (38%) mucositi s was observed, with the oropharynx 
as the main site. This is due to the fact that most pati ents 
in the sample presented oropharyngeal and oral cavity 
tumors. In literature, we found a study of head and neck 
cancer pati ents submitt ed to diﬀ erent treatment types: 
concomitant radiotherapy and chemotherapy, conventi al 
or hyperfracti onated radiotherapy, or chemotherapy only. 
The presented results were very close to those found in 
this study, in which 83% of pati ents presented some grade 
of mucositi s; the moderate grade predominated in 35%(17). 
In another study of head and neck cancer pati ents sub-
mitt ed to diﬀ erent treatment modes, however, 91% of 
pati ents developed some grade of mucositi s, but grade 3 
(60%) predominated(18).
Higher mucositi s incidence levels were found between 
the third and sixth weeks of treatment, with a predomi-
Table 1- Interrupted (IT) and non-interrupted (NIT) treatment 
due to mucositis classifi ed according to CTC 2.0 - São Paulo – 
2005/2006
Grade 2* non-interrupted treatment (NIT); 
Grade 2 ** interrupted treatment (IT)
NIT
Grade 0.1 and 2*
N (%)
IT
Grade 2** e 3
N (%)
Total
N (%)
P
Age range
Up to 60years
More than 60 years
Gender
Female
Male
Race
Black
White
Hypertension
Yes
No
Diabetes
Yes
No
Smoking
Smoker
Former smoker
Non smoker
Staging
II
III
IVA
IVB
Surgery
Yes
No
21 (67.7)
13 (68.4)
3 (60)
31 (68.9)
7 (63.6)
27 (69.2)
10 (66.7)
24 (68.6)
0
34 (72.3)
7 (77.8)
25 (64.1)
2 (100)
4 (100)
6 (60)
19 (63.3)
5 (83.3)
19 (73.1)
15 (62.5)
10 (32.2)
6 (31.5)
2 (40)
14 (31.1)
4 (36.3)
12 (30.8)
5 (33.3)
11 (31.4)
3 (100)
13 (27.7)
2 (22.2)
14 (35.9)
0
0
4 (40)
11 (36.7)
1 (16.7)
7 (26.9)
9 (37.5)
31 (100)
19 (100)
5 (100)
45 (100)
11 (100)
39 (100)
15 (100)
35 (100%)
3 (100)
47 (100)
9 (100)
39 (100)
2 (100)
4 (100)
10 (100)
30 (100)
6 (100)
26 (100)
24 (100)
0.96 (NS)
0.60 (NS)
0.49 (NS)
0.57 (NS)
0.02*
0.44 (NS)
0.37 (NS)
0.54 (NS)
nance of grade 1 and 2 reacti ons. Another study shows 
higher incidence levels of mucositi s between the third 
and seventh week of treatment, with a predominance of 
grade 3, when pati ents were treated with concomitant 
radiotherapy and chemotherapy, but with altered frac-
ti onati on; which could justi fy the higher incidence level 
of grade 3(18). Another factor is that, in the present study, 
some pati ents’ treatment was interrupted when they suf-
fered from grade 2 mucositi s, which did not permit the 
evoluti on of toxicity. In literature, we found studies that 
aﬃ  rm that, aft er one or two weeks of radiotherapy, oral 
erythema can be verifi ed. Aft er the second week, with 
about 20 Gy, edema can be verifi ed; the erythema is no 
longer that visible due to the pressure exerted on the cap-
illary vessels; this is provoked by the accumulati on of ex-
travascular liquid. Aft er 3 weeks, with about 30Gy, vascu-
lar permeability is enhanced, contributi ng to increase the 
edema(19-20). Based on these studies, it is perceived that 
the signs become more evident as from the third week, 
without ignoring individual variati ons in responses.
As for individual clinical factors, our results showed 
that age was not an important factor for mucositi s sever-
ity. Some authors menti on that that the chance of muco-
siti s decreases with age. This is supposedly due to the low 
rate of cell replicati on in elderly pati ents, as cells with high 
mitoti c acti vity are more sensiti ve to radiotherapy and 
chemotherapy. It should be highlighted that the mean age 
of the study parti cipants was lower (57.52 years) in com-
parison with the literature (61.3 and 60.7 years)(9,17).
Regarding smoking, this factor showed no stati sti cal 
signifi cance, probably due to the low incidence level of 
smokers in our sample. The results showed that (16%) ad-
mitt ed smoking during treatment, and only two had their 
treatment interrupted because of the mucositi s. Research 
is found in the literature with diverging results; while 
some did not observe infl uence from smoking on mucosi-
ti s, others aﬃ  rmed that smoking exerted infl uence when 
the irradiated volume was smaller(10-11). It should be taken 
into account that, in these studies, pati ents were submit-
ted to diﬀ erent treatments.
Concerning diabetes, although a small number of pa-
ti ents in our sample (6%) presented the disease, 100% had 
their treatment interrupted due to the severity of the mu-
cositi s, as evidenced by the stati sti cal signifi cance. In lit-
erature, we found a research that observed that oral cav-
ity and oropharyngeal cancer pati ents who were diabeti cs 
and submitt ed to radiotherapy with altered fracti oning 
were at greater risk of developing grade 3 and 4 muco-
siti s(17). Furthermore, studies were observed in which the 
authors aﬃ  rm that, as a systemic disease, diabetes can in-
fl uence mucositi s severity, and that this pathology should 
be taken into account in pati ents receiving head and neck 
irradiati on(21).
According to the literature, type 1 and 2 diabetes pa-
ti ents are at greater risk of developing gingiviti s and peri-
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odontal disease. This is due to impaired healing aft er rap-
id collagen degradati on by metalloproteinase enzymes. 
In additi on, the infl ammatory process is accelerated, 
which hampers healing, enhances monocyte response, 
induces high levels of glycosylated proteins, increases 
the advanced glycati on end products (AGEs) in ti ssues 
and decreases the chemotaxis of neutrophils(16,21-22). 
Thus, based on the above informati on and the present 
study results, we believe that diabeti c pati ents submit-
ted to radiotherapy and chemotherapy, treatments that 
induce infl ammati on, can present predispositi on to the 
development of more severe mucositi s, due to factors 
sensiti zing the oral mucosa.
CONCLUSION
When analyzed on the whole, the present study data 
show that head and neck cancer pati ents submitt ed to con-
comitant radiotherapy and chemotherapy predominantly 
present grade 1 and 2 mucositi s between the third and 
sixth week of treatment. Among individual pati ent, disease 
and treatment characteristi cs, only diabetes enhanced the 
development of severe mucositi s. Therefore, we believe 
that diabeti c pati ents can benefi ts from more frequent 
monitoring during treatment, including specifi c orientati on 
and care, such as glucose and medicati on control. It is im-
portant for nurses to heed these parameters, considering 
that, in view of their presence at the radiotherapy and che-
motherapy sectors, they can collaborate to enhance treat-
ment and improve pati ents’ quality of life.
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